Pancragen 20 mg
$26.40
Pancragen 20 mg – Peptide Hubs
Pancragen is an organ-specific peptide complex designed to support pancreatic health, insulin signaling, and beta-cell activity. Derived from natural cytomedin peptides targeting the pancreas, Pancragen may regulate gene expression, enhance tissue repair, and support glucose metabolism in research settings. Peptide Hubs provides Pancragen in a 20 mg lyophilized format suitable for advanced metabolic and endocrine research.
Mechanism of Action
Pancragen's mechanism focuses on restoring pancreatic tissue function at the molecular level. The short peptides in Pancragen bind to nuclear structures and modulate gene expression, potentially enhancing insulin production and protecting beta cells. This mechanism aligns with cytogenetic peptide research as discussed in this NIH article on peptide bioregulators.
Primary Research Applications
- Pancreatic regeneration and beta-cell support studies
- Insulin pathway modulation research
- Preclinical models of diabetes and metabolic syndrome
- Endocrine and glucose regulation studies
Pancragen is frequently combined with Semaglutide or MOTS-c in research focused on metabolic and glycemic regulation. For oxidative stress and mitochondrial protection, Humanin is a common stack. DNA integrity and cellular repair models may also include FOX04-DRI or L-Glutathione.
Suggested Experimental Use
- Dosage: 20–40 mg per week (e.g. 10 mg 2–4x/week)
- Administration: Subcutaneous injection in preclinical settings
- Duration: Typically 4–6 weeks in pancreas-focused protocols
